ClinConnect ClinConnect Logo
Search / Trial NCT06888518

Multistrain Probiotics Against Bacterial Vaginosis

Launched by INSTITUT ALLERGOSAN PHARMA GMBH · Mar 20, 2025

Trial Information

Current as of April 29, 2025

Terminated

Keywords

Bacterial Vaginosis Vaginal Dysbiosis Probiotics

ClinConnect Summary

If bacterial vaginosis (BV) is detected using the Nugent score (= gold standard for studies) and Amsel criteria, the patient in question is eligible for the study, provided the following additional criteria are met:

* \>16 years of age
* Proof of BV using the Nugent Score (≥ 6)
* Written informed consent for the study (the document is available in printed form in the study folder). Additional parental information is available for underage patients

Please also note the following exclusion criteria:

* Consumption of other probiotics within the last 4 weeks
* Pregnancy, breastfeeding
* Infe...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 16 years
  • Proof of BV using the Nugent Score (\> 6)
  • Written informed consent for the study (the document is available in printed form in the study folder).
  • Additional parental information is available for underage patients
  • Exclusion Criteria:
  • Consumption of other probiotics within the last 4 weeks
  • Pregnancy, breastfeeding
  • Infections of the urogenital tract
  • Participation in another study
  • Infection with other vaginal germs or vaginal mycosis
  • Hepatitis B, C or HIV infection
  • Planned hospitalisation during the intervention period

About Institut Allergosan Pharma Gmbh

Institut Allergosan Pharma GmbH is a leading clinical research organization specializing in the development of innovative therapeutic solutions for allergic and autoimmune diseases. With a commitment to advancing healthcare, the company focuses on conducting rigorous clinical trials that adhere to the highest scientific and ethical standards. Leveraging a team of experienced professionals and state-of-the-art technology, Institut Allergosan Pharma GmbH aims to bring novel treatments to market, improving patient outcomes and enhancing quality of life for individuals affected by chronic conditions.

Locations

Vienna, , Austria

Patients applied

0 patients applied

Trial Officials

Doris Maria Gruber, Univ. Prof. Dr.

Principal Investigator

Wahlarztordination Wien, Lainzerstrasse 147, A-1130 Wien

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported